📹 Video Revolutionary potential $CRVS novel oral ITK inhibitor #soquelitinib upstream in T-cell activation pathway may lead to curative-like disease control for atopic dermatitis Already evidence for benefit to last months and potential to maybe last years in an immune reset.

ITK inhibition w/ $CRVS #soquelitinib as Signal 1 modifier should lead to epigenetic changes that alter T-cells and how they respond, this is already showing up in data. ITKi = Signal 1 control = Disease Modifying, Long-Lasting Benefit Off Therapy Cytokine Blockade = Signal 3 effect = Symptom Control, Requires Constant Therapy Science explanation more detail, not in video⤵️ Why Signal 1 (ITK) inhibition is more likely to create durable T-cell reprogramming 1) Signal 1 sits upstream of chromatin-controlling transcription factors ITK is a central node in TCR signaling, linking the receptor to PLCγ1 and the downstream key (3) three pathways: 1) Ca²⁺/NFAT, 2) PKCθ/NF-κB, and 3) Ras/MAPK/AP-1 pathways. NFAT, AP-1, and NF-κB do more than drive short-term cytokine output. They also regulate chromatin accessibility and recruit co-activators or co-repressors that add or remove epigenetic marks. During early activation, the timing and balance of NFAT and AP-1 is especially important. Strong, coordinated signaling favors productive effector programs, while NFAT activity without adequate AP-1 support is associated with tolerance-like states such as anergy or exhaustion that can be relatively persistent. 2) Signal 1 intensity determines fate choices that become stabilized Key T-cell fates are established during priming and then reinforced by feed-forward transcriptional circuits and epigenetic consolidation. By dampening TCR signal propagation, ITK inhibition can reduce expansion of high-avidity pathogenic clones, shift differentiation away from strongly polarized effector states, and limit establishment or maintenance of tissue-resident inflammatory populations depending on context. Because these effects reshape both the composition and the functional programming of the responding T-cell pool, the resulting changes can persist even after the drug is withdrawn. Contrast this with Signal 3 approaches that focus on the cytokine effector function only. Practically, Signal 3 blockade tends to behave like a dimmer switch on effector function rather than a re-wiring tool for the T-cell repertoire. As a result drugs targeting Signal 3 like Dupilumab, Lebrikizumab and Upadacitinib see disease rebound toward baseline when the blockade is removed, because the upstream TCR-driven antigen specificity and memory remain intact and can re-express the program when the cytokine environment returns.

This model upturns entire way autoimmune diseases are treated and puts franchises that require life-long drug use for disease reduction at risk: $SNY $REGN #Dupixent, $ABBV #Upadacitinib, $LLY #Lebrikizumab, etc It shows the massive potential of $CRVS drug #soquelitinib to change industry: 1. explains why SQL can work on dupi and JAKi failed AD patients as it targets Signal 1 2. shows why patients will not need to take SQL for years, but rather just weeks or months to get the immune rebalance 3. potential for long drug holidays during long-lasting disease control post-treatment 4. Patients on SQL for short duration significantly reduces any potential risk of long-term use... there will not likely be long-term chronic use, but rather short therapy windows with long-lasting benefit.

The kind of video I can easily show to friends and they understand. Thanks again

such clarity and so well explained👍👏